GLP-1 Receptor Agonists as a Breakthrough in Metabolic Therapy The current gold-standard pharmacological interventions against obesity and T2D are glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as semaglutide and liraglutide
This week's Pharmaville editorial covers iBio's approach to that shift
Related themes touched on here include Melanotan 2.
Sources: USA Today, JAMA, JAMA Ophthalmology, FDA, Reuters, KFF, MDL Update, Drugwatch, About Lawsuits
Managing semaglutide side effects through diet Every common semaglutide side effect has a dietary component
Trava Health offers expert-guided NAD+ therapy in Bossier City, ensuring patients receive professional support and a personalized treatment plan for long-term health benefits